查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1828017

脑膜炎双球菌疫苗市场（按疫苗类型、年龄层、配方、分销管道、最终用户和适应症划分）—全球预测，2025-2032 年

Meningococcal Vaccines Market by Vaccine Type, Age Group, Formulation, Distribution Channel, End User, Indication - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年脑膜炎疫苗市场规模将达到 137.4 亿美元，复合年增长率为 11.03%。

主要市场统计数据
基准年2024年 59.5亿美元
预计2025年 66亿美元
预测年份：2032年 137.4亿美元
复合年增长率（%） 11.03%

不断发展的公共卫生、临床和技术格局正在再形成脑膜炎球菌疫苗相关人员的策略重点

全球脑膜炎双球菌疫苗格局正处于关键时刻，抗原设计的进步、疫苗接种建议的扩展以及公共卫生重点的不断演变，共同塑造着疫苗的格局。临床开发正从传统的多醣方法向结合物和蛋白质次单元平台迈进，从而提高疫苗的保护持久性并适应不同年龄层。同时，监管途径也日趋完善，以便在疫情爆发期间进行快速审查，这需要研发机构、监管机构和公共卫生机构之间更紧密的合作。这项动态凸显了涵盖临床开发、生产规模扩大、供应链安全和支付方参与的整合策略的重要性。

随着相关人员重新评估其长期策略，他们必须在临床表现与现实世界交付挑战之间取得平衡。疫苗研发人员越来越关注疫苗功效以外的其他属性，例如耐热性、便于大规模宣传活动和常规接种的剂型，以及专为单剂量物流设计的配方。医疗保健系统和免疫接种项目优先考虑可预测的供应和灵活的采购方案，而研究机构则强调监测以发现血清群的变化。这些因素共同构成了一个复杂的营运环境，其中跨部门协调对于将科学进步转化为病菌感染负担的显着减轻至关重要。

科学突破、监管敏捷性和采购创新如何加速脑膜炎双球菌疫苗计画的能力和应对力

近期的技术和政策变化正在改变脑膜炎双球菌疫苗的研发、生产和交付方式。分子抗原设计和结合化学的进展使候选疫苗具有更广泛的血清群覆盖范围和更高的免疫抗原性。与这些科学进步相辅相成的是製造创新，包括模组化和一次性系统，这些创新缩短了前置作业时间，并实现了区域规模的灵活生产。

在政策方面，公共卫生部门正越来越多地采用基于强化流行病学监测和建模的适应性疫苗接种政策。这使得人们更加重视制定个人化策略，这些策略将当地血清群流行情况、人群免疫状况以及旅行和大型集会等风险因素纳入考量。同时，采购机制也不断发展，集中采购、长期采购协议和预先市场承诺等方式越来越受到青睐，成为稳定供应和鼓励产能投资的手段。总而言之，这些变化正在降低技术和营运门槛，并为扩大覆盖范围和更灵活地应对疫情压力创造新机会。

评估 2025 年关税变化对製造选择、筹资策略、供应链弹性和临床供应物流的多方面影响

2025年实施的关税调整将对脑膜炎双球菌疫苗生态系统产生多方面的影响，对供应链、生产决策和筹资策略产生直接和间接的影响。关税增加了进口投入的成本，包括专用试剂、一次性耗材和成品疫苗的运输，促使製造商和采购商重新评估其筹资策略。为此，一些製造商正在扩大其区域製造地或协商长期供应商协议，以保护其营运免受关税波动的影响。此类调整往往有利于拥有一体化供应链和有资本投资本地生产能力的组织。

此外，关税也会影响公共部门的采购，迫使卫生当局和全球合作伙伴重新评估总到岸成本、调整采购计画或在可行的情况下优先考虑国内采购方案。这些动态也会影响临床试验供应物流，因为对在临床实验药物成分征收进口关税会增加营运复杂性。重点，关税正在鼓励製造商和政策制定者之间进行更密切的合作，以製定缓解策略，例如免除基本卫生用品的关税、协调疫苗成分的分类以及支持扩大区域灌装和成品产能。虽然关税会造成短期成本压力，但它们也会催化供应链弹性和在地化策略的结构性转变，相关人员可以利用这些转变来降低未来中断的风险。

分析疫苗类型、年龄层、配方、分销管道、最终用户和适应症的需求驱动因素以及临床和商业性影响，以製定有针对性的策略

要深入了解市场，需要专注于几个细分领域，这些领域将影响需求趋势、临床策略和商业化路径。疫苗类型包括结合疫苗、多醣体疫苗和蛋白质次单元，每种疫苗的免疫特性和对目标族群的适用性各不相同。结合疫苗因其免疫记忆和在儿童和青少年常规免疫接种中的效用而持续受到关注；而多醣疫苗在应对特定疫情或作为补充工具方面可能仍然具有重要意义。蛋白质次单元候选疫苗因其广泛的交叉保护作用和更高的耐受性而日益受到关注，有可能扩大其在成人和老年人群中的应用。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 血清群流行率的增加导致多效价脑膜炎双球菌 B 疫苗扩展到欧洲各地的青少年疫苗接种计划
  • 将脑膜炎双球菌四价结合疫苗纳入北美青少年和大学入学常规免疫计划
  • 疫苗製造商与公共卫生机构建立策略伙伴关係，加强撒哈拉以南非洲的疫情应变能力
  • 开发脑膜炎双球菌 ACWY 和其他儿童病原体的联合疫苗，以简化婴儿疫苗接种计划
  • 疫苗犹豫的出现影响了高所得国家年轻人的脑膜炎球菌疫苗接种覆盖率
  • 采用新型结合技术提高下一代脑膜炎双球菌疫苗的免疫抗原性并降低反应原性
  • 动态血清群替代模式对全球市场区域疫苗配方与筹资策略的影响

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 脑膜炎双球菌疫苗市场（依疫苗类型）

  • 加入
  • 多醣
  • 蛋白质次单元

9. 脑膜炎双球菌疫苗市场（依年龄层）

  • 青春期
  • 成人
  • 老年人
  • 孩子们

10. 脑膜炎双球菌疫苗市场（按剂型）

  • 多剂量
  • 单一剂量

11. 脑膜炎双球菌疫苗市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

12. 脑膜炎双球菌疫苗市场（依最终用户）

  • 诊所
  • 医院
  • 研究所
  • 疫苗接种中心

13. 脑膜炎双球菌疫苗市场（按适应症）

  • 疫情应对
  • 定期预防
  • 旅行者疫苗接种

14. 脑膜炎双球菌疫苗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章脑膜炎双球菌疫苗市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 脑膜炎双球菌疫苗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bharat Biotech Ltd.
    • GlaxoSmithKline PLC
    • Incepta Pharmaceuticals Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Serum Institute of India Pvt. Ltd.
    • Taj Pharmaceuticals Limited
Product Code: MRR-430D42AA101A

The Meningococcal Vaccines Market is projected to grow by USD 13.74 billion at a CAGR of 11.03% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.95 billion
Estimated Year [2025] USD 6.60 billion
Forecast Year [2032] USD 13.74 billion
CAGR (%) 11.03%

Contextualizing the evolving public health, clinical, and technological landscape that is reshaping strategic priorities for meningococcal vaccine stakeholders

The global landscape for meningococcal vaccines has entered a pivotal phase, shaped by advances in antigen design, expanded immunization recommendations, and evolving public health priorities. Clinical development has broadened beyond traditional polysaccharide approaches, with conjugate and protein subunit platforms offering improved durability of protection and suitability across diverse age groups. Concurrently, regulatory pathways have matured to accommodate accelerated reviews in outbreak contexts, prompting closer collaboration among developers, regulators, and public health agencies. These dynamics have elevated the importance of integrated strategies that span clinical development, manufacturing scale-up, supply chain security, and payer engagement.

As stakeholders reassess their long-term strategies, they must balance clinical performance with real-world delivery challenges. Vaccine developers are increasingly focused on attributes beyond efficacy, including thermostability, presentation formats that facilitate mass campaigns or routine schedules, and formulations designed for single-dose logistics. Health systems and immunization programs are prioritizing predictable supply and flexible procurement instruments, while research institutions emphasize surveillance to detect serogroup shifts. Together, these elements create a complex operational environment where cross-disciplinary coordination is essential for translating scientific progress into measurable reductions in meningococcal disease burden.

How scientific breakthroughs, regulatory agility, and procurement innovations are collectively accelerating capability and responsiveness in meningococcal vaccine programs

Recent technological and policy shifts are transforming how meningococcal vaccines are developed, manufactured, and delivered. Advances in molecular antigen design and conjugation chemistry have enabled candidates with broader serogroup coverage and improved immunogenicity, while adjuvant science and protein engineering have expanded the toolkit for eliciting robust immune responses across age cohorts. These scientific strides are complemented by innovations in manufacturing technologies, such as modular and single-use systems, which reduce lead times and support flexible production at regional scales.

On the policy front, public health authorities are increasingly adopting adaptive immunization policies informed by enhanced epidemiologic surveillance and modeling. This has shifted attention toward tailored strategies that consider local serogroup prevalence, population immunity profiles, and risk factors such as travel and mass gatherings. Simultaneously, procurement mechanisms are evolving; pooled purchasing, long-term purchase agreements, and advance market commitments are gaining traction as instruments for stabilizing supply and encouraging investment in capacity. Taken together, these transformative shifts are lowering technical and operational barriers, creating new opportunities to expand coverage and respond more nimbly to outbreak pressures.

Assessing the multifaceted implications of 2025 tariff changes on manufacturing choices, procurement strategies, supply chain resilience, and clinical supply logistics

The introduction of tariff adjustments in 2025 has had multifaceted implications for the meningococcal vaccine ecosystem, with direct and indirect effects on supply chains, manufacturing decisions, and procurement strategies. Tariffs raise the cost of imported inputs such as specialized reagents, single-use consumables, and finished vaccine shipments, prompting manufacturers and purchasers to reassess sourcing strategies. In response, some producers are expanding regional manufacturing footprints or negotiating longer-term supplier agreements to insulate operations from tariff volatility. Such adjustments tend to favor organizations with integrated supply chains or the capital to invest in localized capacity.

Moreover, tariffs influence the calculus of public-sector procurement. Health authorities and global partners reassess total landed costs and may adjust procurement schedules or prioritize domestically produced options when feasible. These dynamics also affect clinical trial supply logistics, where import duties on investigational materials can increase operational complexity. Importantly, tariffs have prompted closer collaboration between manufacturers and policymakers to design mitigation strategies, including tariff exemptions for essential health commodities, harmonized classification of vaccine components, and support for scaling regional fill-and-finish capabilities. While tariffs create short-term cost pressures, they also catalyze structural shifts in supply chain resilience and localization strategies that stakeholders can leverage to reduce future disruption risks.

Dissecting demand drivers and clinical-commercial implications across vaccine type, age cohort, formulation, distribution channel, end user, and indication to inform targeted strategies

A granular understanding of the market requires attention to several segmentation dimensions that affect demand dynamics, clinical strategy, and commercialization pathways. Based on Vaccine Type, the landscape is studied across Conjugate, Polysaccharide, and Protein Subunit approaches, each offering distinct immunological profiles and suitability for target populations. Conjugate vaccines continue to be favored for their immunological memory and utility in routine pediatric and adolescent schedules, while polysaccharide formulations may retain relevance for specific outbreak responses or as complementary tools. Protein subunit candidates are attracting interest where broad cross-protection and improved tolerability support expanded use in adults and older age groups.

Based on Age Group, analysis covers Adolescent, Adult, Geriatric, and Pediatric cohorts, recognizing that immunization strategies and clinical endpoints vary by life stage. Pediatric programs emphasize early-life protection and integration with routine schedules, adolescents represent a key group for catch-up and school-based campaigns, adults and geriatric populations require tailored immunogenicity and safety assessments, and travelers or occupational groups create targeted demand. Based on Formulation, the landscape examines Multi Dose and Single Dose presentations, with single-dose formats enhancing campaign efficiency and multi-dose vials offering cost advantages but requiring careful cold-chain and safety safeguards. Based on Distribution Channel, the study considers Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy pathways, acknowledging shifting patient behaviors, digital prescribing trends, and the role of hospital systems in centralized immunization delivery. Based on End User, focus areas include Clinics, Hospitals, Research Institutes, and Vaccination Centers, each with distinct procurement practices, storage capabilities, and administration workflows. Based on Indication, the market is examined across Outbreak Response, Routine Prophylactic, and Traveler Immunization use cases, which guide product selection, regulatory obligations, and deployment timelines. Together, these segmentation lenses provide a nuanced framework for aligning clinical development priorities, commercialization strategies, and public health planning.

Exploring how distinct epidemiology, infrastructure maturity, and procurement practices across global regions influence vaccine selection, delivery, and capacity priorities

Regional dynamics materially shape clinical priorities, procurement behaviors, and operational requirements for meningococcal vaccines. In the Americas, surveillance capacity and established immunization programs drive consistent demand for routine schedules, while episodic outbreaks and travel-related exposures continue to create pockets of urgent need. Health systems in this region place emphasis on integrated procurement mechanisms and coordination between national immunization programs and subnational purchasers. Cold-chain infrastructure and high vaccination coverage in many settings facilitate deployment of both multi-dose and single-dose formats, yet disparities remain that require tailored distribution strategies.

Europe, Middle East & Africa exhibits wide heterogeneity: high-income parts of Europe maintain rigorous vaccine monitoring and policy processes that prioritize long-term protection, whereas regions within the Middle East and Africa contend with variable surveillance infrastructure, lower baseline coverage in some areas, and periodic large-scale outbreaks that necessitate rapid mass vaccination responses. Capacity building for laboratory confirmation and serogroup surveillance is a priority across several jurisdictions. The Asia-Pacific region presents a combination of large-scale routine immunization platforms, growing domestic manufacturing ambitions, and diverse epidemiologic profiles. Urban concentration and increasing travel create ongoing demand for traveler immunization, while investments in regional manufacturing and regulatory harmonization are enhancing supply security. Collectively, these regional patterns inform how stakeholders prioritize product portfolios, manufacturing investments, and public-private collaboration.

Mapping the competitive landscape where scientific differentiation, manufacturing agility, and strategic partnerships determine product access and long-term program success

Competitive dynamics in the meningococcal vaccine arena are shaped by a mixture of established vaccine manufacturers, emerging biotechnology firms, contract manufacturers, and specialized service providers. Incumbent manufacturers maintain advantages through proven clinical track records, broad regulatory approvals, and established production lines, while newer entrants frequently differentiate on antigen innovation, novel adjuvants, or manufacturing agility. Strategic partnerships and licensing arrangements have become a primary vehicle for accelerating access to complementary capabilities, such as conjugation expertise or regional fill-and-finish capacity, enabling faster route-to-market for promising candidates.

In parallel, contract manufacturing organizations and fill-and-finish specialists play an increasingly strategic role by offering scalable, geographically distributed capacity that can mitigate single-point failures. Collaboration between commercial teams and public health purchasers is also evolving; outcomes-based contracting, long-term supply agreements, and coordinated technology transfers are mechanisms being used to secure sustained access. Finally, alliances between academic researchers and industry accelerate translational work, particularly where novel protein subunit approaches require iterative clinical evaluation. Overall, organizations that combine scientific differentiation with flexible manufacturing, robust regulatory planning, and proactive stakeholder engagement are positioned to capture the most durable value.

Clear, prioritized actions for manufacturers, policymakers, and supply chain leaders to convert scientific progress into scalable, resilient, and equitable vaccine access

Industry leaders should adopt a prioritized set of actions to convert scientific advances into resilient, accessible immunization programs. First, integrate supply chain risk assessments into early product planning to identify critical inputs and upstream vulnerabilities, then pursue diversification or localized production where strategic. Second, align clinical development with end-user operational realities by designing formulations and delivery formats that reduce cold-chain reliance and facilitate administration across pediatric, adolescent, adult, and geriatric settings. Third, cultivate proactive engagement with regulators and public health agencies to streamline approval pathways for outbreak responses and to secure predictable procurement commitments.

Additionally, pursue scalable manufacturing models that leverage modular facilities and contract partners to accelerate capacity expansion without overextending capital commitments. Strengthen surveillance partnerships with public health laboratories and academic centers to detect serogroup shifts and to inform adaptive immunization strategies. Finally, invest in evidence generation that demonstrates real-world effectiveness, safety across age cohorts, and health economic value to support inclusion in immunization schedules and to facilitate payer negotiations. By executing these priorities in parallel, organizations can improve their ability to respond to outbreaks, expand routine protection, and sustain reliable supply.

A transparent and rigorous mixed-methods research approach combining primary expert interviews and systematic secondary review to produce validated, actionable insights

The research methodology underpinning this analysis combined structured primary research with systematic review of peer-reviewed literature, regulatory documents, and publicly available surveillance reports to ensure a rigorous evidence base. Primary research included qualitative interviews with immunization program leaders, clinical investigators, manufacturing experts, and procurement specialists to capture operational realities and strategic priorities. Secondary sources comprised scientific publications, regulatory guidance documents, clinical trial registries, and technical reports that inform product attributes, safety profiles, and implementation considerations.

Data synthesis followed a transparent process: findings from interviews and document reviews were triangulated to identify consistent themes and to highlight areas of divergence. Quality assurance steps included source validation, cross-referencing of clinical and regulatory data, and expert review by independent advisors with domain experience in vaccinology, public health policy, and pharmaceutical manufacturing. Throughout, ethical standards and confidentiality protocols were maintained for interview subjects, and analytical assumptions were explicitly documented to ensure reproducibility of insights and to support evidence-based decision-making.

Converging scientific innovation and operational resilience form the foundation for sustained progress in reducing meningococcal disease through targeted vaccine strategies

In summary, the meningococcal vaccine landscape is at an inflection point driven by technical innovation, evolving policy frameworks, and operational shifts in supply and procurement. Scientific advances in conjugate technologies, protein subunits, and manufacturing methodologies are creating new options that better match the needs of diverse age cohorts and use cases. At the same time, policy evolution and procurement experimentation are enabling more adaptive responses to outbreaks and improving alignment between public health goals and commercial incentives. These converging factors underscore the importance of integrated strategies that combine clinical excellence with supply chain resilience and stakeholder collaboration.

Going forward, success will hinge on the ability of stakeholders to translate immunologic improvements into products that are logistically feasible and economically viable for routine programs and emergency responses. Investments in regional capacity, strategic partnerships, and surveillance infrastructure will be critical to sustaining long-term access and ensuring that clinical gains translate into measurable reductions in disease burden. For decision-makers, the imperative is to pursue coordinated planning across development, manufacturing, regulation, and delivery so that innovations reach populations in need with speed, reliability, and equity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of multivalent meningococcal B vaccines into adolescent immunization programs across Europe due to rising serogroup prevalence
  • 5.2. Integration of meningococcal quadrivalent conjugate vaccines with routine adolescent and college-entry immunization schedules in North America
  • 5.3. Strategic partnerships between vaccine manufacturers and public health agencies to enhance outbreak response capabilities in sub-Saharan Africa
  • 5.4. Development of combination vaccines targeting meningococcal ACWY and other pediatric pathogens to streamline immunization schedules for infants and toddlers
  • 5.5. Emergence of vaccine hesitancy impacting meningococcal immunization coverage rates among young adults in high-income countries
  • 5.6. Adoption of novel conjugation technologies to improve immunogenicity and reduce reactogenicity in next-generation meningococcal vaccines
  • 5.7. Impact of dynamic serogroup replacement patterns on regional vaccine formulation and procurement strategies across global markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Meningococcal Vaccines Market, by Vaccine Type

  • 8.1. Conjugate
  • 8.2. Polysaccharide
  • 8.3. Protein Subunit

9. Meningococcal Vaccines Market, by Age Group

  • 9.1. Adolescent
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Meningococcal Vaccines Market, by Formulation

  • 10.1. Multi Dose
  • 10.2. Single Dose

11. Meningococcal Vaccines Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Meningococcal Vaccines Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Research Institutes
  • 12.4. Vaccination Centers

13. Meningococcal Vaccines Market, by Indication

  • 13.1. Outbreak Response
  • 13.2. Routine Prophylactic
  • 13.3. Traveler Immunization

14. Meningococcal Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Meningococcal Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Meningococcal Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Astellas Pharma Inc.
    • 17.3.2. AstraZeneca PLC
    • 17.3.3. Bharat Biotech Ltd.
    • 17.3.4. GlaxoSmithKline PLC
    • 17.3.5. Incepta Pharmaceuticals Ltd.
    • 17.3.6. Merck & Co., Inc.
    • 17.3.7. Novartis AG
    • 17.3.8. Pfizer Inc.
    • 17.3.9. Sanofi S.A.
    • 17.3.10. Serum Institute of India Pvt. Ltd.
    • 17.3.11. Taj Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MENINGOCOCCAL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 261. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 268. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 269. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 303. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 310. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 311. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 317. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 324. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 325. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 328. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (US